Evidence map›Paper›PMID 34592998›Full record

Observational studyRespiratory research2021

Hospitalizations in patients with idiopathic pulmonary fibrosis.

Hyun J Kim, Laurie D Snyder, Ayodeji Adegunsoye, Megan L Neely, Shaun Bender, Eric S White, Craig S Conoscenti, Mary E Strek, IPF-PRO Registry Investigators

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01915511 recruitingnot on this map

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry

Typeobservational_patient_registrySponsorDuke UniversityRan2014 to 2031Enrolled3,000ConditionsIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Outcomes ofJGH open : an open access journal of gastroenterology and hepatology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Hospitalizations as Clinical Trials Endpoint in Interstitial Lung Disease: Are We There Yet?American journal of respiratory and critical care medicine · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hyun J KimUniversity of Minnesota, Minneapolis, MN, USA. kimxx015@umn.edu.
Laurie D SnyderDuke Clinical Research Institute, Durham, NC, USA.
Ayodeji AdegunsoyeSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, USA.
Megan L NeelyDuke Clinical Research Institute, Durham, NC, USA.
Shaun BenderBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Eric S WhiteBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Craig S ConoscentiBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Mary E StrekSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, USA.
IPF-PRO Registry Investigators
University of Chicago · USBoehringer Ingelheim (United States) · USUniversity of Minnesota · USClinical Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF.

methodsThe IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models.

resultsA total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater.

conclusionsData from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.

Indexed as

HospitalizationAgedFemaleHospital MortalityHumansIdiopathic Pulmonary FibrosisMalePatient DischargePatient ReadmissionPrognosisRegistriesRespiration, ArtificialRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsInterstitial lung diseaseMechanical ventilationMortalityPulmonary fibrosisRespiratory function tests

Identifiers

PMID34592998
PMCPMC8481759
OpenAlexW3203247021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.